News

Roman Bronfenbrener, MD, discusses how AI-generated patient diagnoses are reshaping dermatology visits and creating new challenges.

Kord Honda, MD, provides his first-line and adjunct treatment strategies for acne in recognition of Acne Awareness Month.

Explore top dermatology conferences and meetings in July 2026 and let us know which ones you'll be attending!

Linda Stein Gold, MD, reviews the recent LATITUDE Atlas head-to-head trial results showing zasocitinib's superiority over deucravacitinib for plaque psoriasis.

One-year phase 3 VELA data showed durable clinical responses, quality-of-life improvements, and no new safety signals for investigational sonelokimab in hidradenitis suppurativa.

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

Christopher Bunick, MD, PhD, discusses the FDA's expanded approval of roflumilast cream 0.3% for plaque psoriasis in children as young as 2 years of age.

AbbVie's upadacitinib received a positive CHMP opinion for severe alopecia areata as FDA review continues in the US.

Learn more about the in-depth topics covered in the June 2026 print issue of Dermatology Times.

A national survey examines the pressures facing independent dermatologists and strategies to strengthen practice performance.

The approval expands the existing indication for adults and children down to age 6, includes intertriginous areas, and removes restrictions on duration of use.

Philip Mease, MD, discusses the FDA's label expansion for guselkumab's inhibition of structural joint damage in psoriatic arthritis.

Dermatology Times is looking back on the top stories in dermatology from the month of June.

Evommune's EVO756 failed to meet the primary end point in a phase 2b trial for chronic spontaneous urticaria, prompting the company to discontinue development for the indication while continuing studies in atopic dermatitis.

Despite often being highly treatable, nonmelanoma skin cancers account for millions of biopsies, procedures, and follow-up visits annually, creating a substantial healthcare burden.

Do nighttime collagen masks actually work or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

The FDA has accepted Replimune's third resubmitted BLA for RP1 plus nivolumab in advanced melanoma, setting an August 2 PDUFA date.

Kord Honda, MD, reviews the hormonal drivers of acne, prevention-focused treatment, and common skin care misconceptions.

An Evolving Paradigms event led by Darrell S. Rigel, MD, MS, compared PD-1/PD-L1 immunotherapies for advanced cutaneous squamous cell carcinoma, with referral guidance and toxicity alerts.

Lim considers mentoring and helping develop the next generation of dermatologists one of his most meaningful contributions to the specialty.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of June.

Raj Chovatiya, MD, PhD, MSCI, co-chair of RAD 2026, highlighted new AD science, type 2 inflammation insights, and emerging therapies—helping clinicians translate immunology advances into better patient care.

Kymera Therapeutics finished enrollment in its phase 2b BROADEN2 trial of KT-621 nearly six months early, moving up topline AD data to year-end 2026.

Andrew Krakowski, MD, encourages involving both caregivers and children in treatment decisions, giving young patients a sense of ownership that can significantly improve adherence.

State melanoma reporting data reveals a striking gap between one Arizon dermatologist's detection rates and his peers, and a possible explanation rooted in how dermoscopy is taught.

Expert guidance from RAD 2026 dispels eczema diet myths, urging symptom-based allergy testing and whole-patient atopic dermatitis care with practical skin, sleep, and lifestyle strategies.

A recent JAAD case report describes congenital depigmentation and progressive posttransplant repigmentation in a child with NHEJ1-related radiosensitive SCID—a pairing not previously documented.

This review of the latest dermatological studies includes insights into vitiligo, including emerging surgical techniques, the impact of social media, camouflage agents, and more.

An international survey shows vitiligo drives stigma, sun avoidance, and daily limits, urging better treatment guidance and mental health support.

Lisa Pruett, MD, FAAD, shares evidence-based acne care, debunks summer retinoid myths, and explains how Glo2Facial oxygenation and exfoliation support clearer skin and fade marks.